

The Association Between Rheumatic Heart Disease and Vitamin D Deficiency: A Comprehensive Analysis of Current Evidence

Recent scientific evidence demonstrates a significant association between rheumatic heart disease (RHD) and vitamin D deficiency, with multiple studies revealing that patients with RHD consistently exhibit lower serum vitamin D concentrations compared to healthy controls. Research from Nepal shows RHD patients have mean vitamin D levels of 39 nmol/L versus 45 nmol/L in controls, with vitamin D insufficiency conferring a 2.59-fold increased risk of developing RHD^[1]. This relationship extends beyond correlation, as seasonal patterns of acute rheumatic fever occurrence align with periods of lowest vitamin D synthesis, and the immunomodulatory effects of vitamin D suggest potential mechanistic pathways linking deficiency to increased susceptibility to rheumatic diseases.

Epidemiological Evidence for the Association

Case-Control Studies in Rheumatic Heart Disease

The most comprehensive investigation of vitamin D status in RHD patients comes from a Nepalese case-control study involving 99 confirmed RHD patients and 97 matched cardiac-healthy controls^[1]. This study revealed that RHD patients demonstrated significantly lower mean serum 25(OH)D concentrations at 39 nmol/L compared to 45 nmol/L in controls (p -value = 0.02)^[1]. More critically, individuals with vitamin D insufficiency (defined as 25-50 nmol/L) exhibited a substantially elevated risk of having RHD, with an odds ratio of 2.59 (95% CI: 1.04–6.50) after adjusting for potential confounders including age, BMI, sex, education, and socioeconomic status^[1].

The prevalence of vitamin D insufficiency and deficiency was remarkably high in both groups, affecting 78% of RHD cases compared to 70% of controls^[1]. This finding suggests that while vitamin D deficiency is endemic in certain populations, RHD patients experience even more severe deficiency states. The study also revealed that nearly half (47%) of RHD cases belonged to the lowest socioeconomic class compared to only 21% of controls, indicating potential confounding factors related to nutritional access and overall health status^[1].

Acute Rheumatic Fever Studies

Research on acute rheumatic fever (ARF), the precursor condition to RHD, provides additional compelling evidence for the vitamin D-rheumatic disease association. A recent 2025 study of 25 ARF patients with active carditis compared to 25 healthy controls found that vitamin D levels at diagnosis were lower in the ARF group, though this difference was not statistically significant when measured across all seasons ($p=0.07$)^[2]. However, when examining seasonal patterns, a more pronounced relationship emerged.

During winter and spring seasons, when vitamin D synthesis is naturally reduced due to limited sunlight exposure, ARF patients demonstrated significantly lower vitamin D levels of 17.54 ± 9.89 $\mu\text{g/L}$ compared to controls at 23.97 ± 9.48 $\mu\text{g/L}$ ($p=0.038$)^[2]. The vitamin D deficiency rate during these seasons reached 47.3% in ARF patients versus only 19.1% in controls, yielding an attributed risk for vitamin D deficiency in ARF carditis of 3.46 (95% CI 1.1–5.14)^[2].

A complementary study from 2017 examining 30 ARF patients against 16 controls found even more dramatic differences, with ARF patients showing significantly lower vitamin D levels of 14.56 ± 8.31 ng/mL compared to 25.41 ± 1.38 ng/mL in controls ($p=0.002$)^[3]. When applying a cutoff of 20 ng/mL for vitamin D deficiency, 77% of ARF patients demonstrated deficiency compared to 50% of controls^[3].

Geographic and Seasonal Patterns

The seasonal clustering of both ARF incidence and vitamin D deficiency provides strong circumstantial evidence for their relationship. ARF and subsequent RHD development show peak incidence during winter and spring months, precisely when vitamin D levels are expected to be lowest due to reduced sunlight exposure^[2] ^[3]. This temporal correlation suggests that vitamin D deficiency may create a permissive environment for the development of rheumatic diseases, particularly in genetically susceptible individuals.

Mechanistic Basis for the Association

Immunomodulatory Effects of Vitamin D

Vitamin D functions as a potent immunomodulatory hormone with effects extending far beyond calcium homeostasis^[4] ^[5] ^[6]. The presence of vitamin D receptors (VDR) in immune cells, including macrophages, dendritic cells, and T lymphocytes, enables vitamin D to directly influence immune responses^[6]. Specifically, vitamin D promotes the development and function of regulatory T cells (Tregs) while suppressing T-helper 1 (Th1) and T-helper 17 (Th17) cell formation^[5] ^[6].

These immunomodulatory effects are particularly relevant to rheumatic diseases, which involve autoimmune processes triggered by molecular mimicry between group A streptococcal antigens and human tissue components^[3]. Vitamin D deficiency may compromise the immune system's ability to appropriately regulate the inflammatory response following streptococcal infection, potentially allowing for the development of cross-reactive antibodies that target cardiac tissues^[3].

Endothelial and Vascular Effects

The mechanism linking vitamin D deficiency to RHD may also involve endothelial dysfunction. Serum 25(OH)D regulates the expression of vascular endothelial growth factor, and deficiency could explain the link between hypovitaminosis D and endothelial dysfunction^[1]. Since extravasation through valvular endothelium appears to be an important step in the valvular lesions characteristic of RHD, vitamin D deficiency could predispose to the endothelial damage that facilitates rheumatic valve disease^[1].

Anti-inflammatory Properties

Vitamin D exhibits significant anti-inflammatory effects through multiple pathways^{[2] [5]}. It suppresses the production of inflammatory cytokines while promoting the secretion of anti-inflammatory mediators like interleukin-10^[5]. In the context of ARF and RHD, this anti-inflammatory capacity could be crucial for limiting tissue damage during the acute inflammatory phase and preventing progression to chronic valvular disease.

Clinical Implications and Disease Severity

Relationship to Disease Activity

Studies examining the relationship between vitamin D status and disease severity in rheumatic conditions have yielded mixed results. In ARF patients, vitamin D levels were not significantly correlated with carditis severity, as patients with mild, moderate, and severe carditis showed similar vitamin D concentrations^[3]. However, patients with carditis overall had lower vitamin D levels compared to those without carditis (25.1 ± 13.5 ng/mL; $p=0.054$)^[3].

The longitudinal follow-up of ARF patients revealed that cardiac parameters improved significantly while vitamin D deficiency rates decreased during the recovery period^[2]. This temporal relationship suggests that vitamin D repletion may contribute to improved outcomes, though causality cannot be definitively established from observational data.

Nutritional Status and Confounding Factors

RHD patients in the Nepalese study demonstrated overall poor nutritional status, with significantly lower body mass index compared to controls (22.6 vs 24.2; 95% CI difference)^[1]. This finding suggests that vitamin D deficiency may be part of a broader pattern of nutritional inadequacy that contributes to increased susceptibility to rheumatic diseases. The high prevalence of vitamin D deficiency even in control populations (70%) indicates that environmental and dietary factors play substantial roles in determining vitamin D status in endemic regions^[1].

Therapeutic Considerations and Research Gaps

Supplementation Evidence in Rheumatic Diseases

While the association between vitamin D deficiency and rheumatic diseases appears robust, evidence for the therapeutic benefits of vitamin D supplementation in established rheumatic conditions remains limited^{[7] [8]}. A systematic review of vitamin D supplementation in immune-mediated rheumatic diseases found that supplementation reduced anti-dsDNA positivity in systemic lupus erythematosus and possibly reduced rheumatoid arthritis recurrence, though the evidence quality was moderate^[8].

The American College of Rheumatology acknowledges vitamin D as emerging as essential in managing multiple rheumatic diseases, particularly rheumatoid arthritis, with normal levels ranging from 30-100 ng/mL^[4]. However, high-quality prospective, double-blind, placebo-

controlled trials specifically examining vitamin D supplementation in RHD prevention or treatment are lacking^[7].

Prevention Strategies

Given the strong epidemiological evidence linking vitamin D deficiency to increased risk of ARF and RHD, maintaining adequate vitamin D status may represent an important prevention strategy, particularly in high-risk populations. The seasonal pattern of ARF occurrence suggests that vitamin D supplementation during winter and spring months could potentially reduce disease incidence^{[2] [3]}.

However, several challenges complicate prevention efforts in endemic regions. Many areas lack food fortification programs, and vitamin D supplementation is not routinely provided to the 5-15 year age group at highest risk for ARF development^[3]. Additionally, the high baseline prevalence of vitamin D deficiency in these populations suggests that environmental factors and limited sun exposure may require comprehensive public health interventions beyond individual supplementation.

Conclusion

The available evidence strongly supports an association between rheumatic heart disease and vitamin D deficiency, with RHD patients consistently demonstrating lower vitamin D levels compared to healthy controls. The relationship appears particularly pronounced during seasons of limited sunlight exposure, aligning with the known seasonal clustering of acute rheumatic fever incidence. The immunomodulatory and anti-inflammatory properties of vitamin D provide plausible mechanistic explanations for this association, suggesting that deficiency may create conditions permissive for the development of autoimmune responses following streptococcal infection.

However, several important research gaps remain. Longitudinal studies are needed to establish causality and determine whether vitamin D deficiency precedes disease development or results from the disease process itself^[1]. Additionally, randomized controlled trials examining vitamin D supplementation for RHD prevention and treatment are necessary to translate epidemiological observations into clinical practice guidelines. Future research should also investigate optimal vitamin D dosing strategies and target populations for intervention in endemic regions where both vitamin D deficiency and rheumatic diseases are prevalent.

The current evidence suggests that maintaining adequate vitamin D status should be considered as part of comprehensive strategies for preventing rheumatic heart disease, particularly in high-risk populations and during seasons of increased vulnerability. However, vitamin D supplementation should be viewed as one component of broader public health efforts addressing the social determinants and infectious disease control measures necessary to reduce the global burden of rheumatic heart disease.

✱✱

1. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7444549/>

2. <https://jcpres.com/article/646>

3. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5512202/>
4. <https://rheumatology.org/patient-blog/vitamins-for-rheumatic-disease-friend-or-foe>
5. <https://www.explorationpub.com/Journals/ei/Article/10039>
6. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9092099/>
7. <https://pubmed.ncbi.nlm.nih.gov/23670134/>
8. https://journals.lww.com/md-journal/fulltext/2017/06090/vitamin_d_supplementation_and_disease_activity_in.9.aspx